a
a
Weather:
No weather information available
HomeHealthTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China’s NMPA

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China’s NMPA

YUPELRI approved by China’s NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China Theravance Biopharma…

No comments

Sorry, the comment form is closed at this time.

Translate »